Feeds:
Posts
Comments

Posts Tagged ‘castration-resistant prostate cancer’

Trial results on new advanced prostate cancer drug will be out soon

Posted in Treatment news, tagged , , , , , , , , , , , , , , , on September 12, 2010| Leave a Comment »

BLOOMBERG BUSINESSWEEK: A US company will next month report the results of its study of abiraterone acetate plus prednisone for the treatment of patients with metastatic advanced prostate cancer, also called castration-resistant prostate cancer. READ MORE>

Read Full Post »

New drugs effective against bone problems caused by hormone treatment of prostate cancer

Posted in Bone loss, Treatment news, tagged , , , , , , , , , , , , , , , on August 5, 2010| Leave a Comment »

URO TODAY: New drugs – still being trialled – are proving effective treatment of prostate cancer bone metastases and prevention of fractures associated with androgen deprivation therapy. READ MORE>

Read Full Post »

Immuno-therapy may prolong lives of men with advanced prostate cancer

Posted in Immunotherapy, tagged , , , , , , , , , , , , , on July 31, 2010| Leave a Comment »

MEDPAGE TODAY: A cellular immuno-therapy appears to prolong survival among men with metastatic, castration-resistant prostate cancer, researchers report. READ MORE>

Read Full Post »

Trial begins on new antagonist drug that takes over after docetaxel-based chemotherapy

Posted in Chemotherapy, Hormone-refactory, PROSTATE CANCER, PROSTATE RESEARCH, Treatment news, tagged , , , , , , , , , , , , , , , on September 25, 2009| Leave a Comment »

MEDICAL NEWS TODAY: A phase 3 clinical trial of the investigational drug MDV3100 for advanced prostate cancer has just begun in the US. READ MORE>

Known as AFFIRM, the trial will evaluate the novel androgen receptor antagonist MDV3100 in men with castration-resistant prostate cancer who were previously treated with .

Read Full Post »

Dutch study looks at what causes prostate cancer to move to its deadly final stage

Posted in Hormone-refactory, PROSTATE CANCER, PROSTATE RESEARCH, Treatment news, tagged , , , , , , , , , , , on August 3, 2009| Leave a Comment »

AUGUST 3: URO TODAY: An understanding of the mechanisms prostate cancer cells use to bypass androgen-deprived conditions, thus moving patients to the hormone refractory stage, is the aim of a new Dutch study. READ MORE>

Knowledge of the molecular and cellular changes that occur during the transition of hormone-naïve to castration-resistant prostate cancer is increasing rapidly. This might provide a window of opportunity for (future) drug development, and for treating patients with these potentially devastating states of disease.

Read Full Post »

PROSTATE RESEARCH: Study looks at management of castration-resistant patients

Posted in Hormone therapy, Hormone-refactory, PROSTATE CANCER, PROSTATE RESEARCH, Treatment news, tagged , , , , , , , , , , , , on June 24, 2009| Leave a Comment »

JUNE 24: URO TODAY: Management of castration-resistant prostate cancer after docetaxel has become an unmet need for which various agents have been investigated. READ MORE>

Read Full Post »

PROSTATE RESEARCH: Study looks at efficacy of drug for castrate-resistant patients

Posted in Hormone-refactory, PROSTATE CANCER, PROSTATE RESEARCH, Treatment debate, Treatment news, tagged , , , , , , , , , , , , on June 19, 2009| Leave a Comment »

JUNE 19: URO TODAY: A new study has explored the efficacy and tolerability of sunitinib, an inhibitor of tyrosine kinase receptors, in men with castration-resistant prostate cancer. READ MORE>

Read Full Post »

PROSTATE TREATMENT: Drug leads to big PSA drop in castrate-reisistant patients

Posted in Hormone-refactory, New prostate drugs, PROSTATE CANCER, PROSTATE RESEARCH, PSA tests, tagged , , , , , , , , , , , , , , , on June 19, 2009| 1 Comment »

JUNE 19: REUTERS HEALTH: Abiraterone acetate leads to significant declines in prostate-specific antigen (PSA) in men with castration-resistant prostate cancer, an aggressive form of the disease. READ MORE>

Read Full Post »